GLP-1s for Maintenance vs Active Loss

Most of the conversation around GLP-1 medications focuses on the dramatic part: the weight that comes off. But for anyone who has reached a goal, a quieter and arguably harder question follows — what now? Using these drugs to actively lose weight and using them to hold a new, lower set point are two different jobs, and the evidence treats them differently.

The case that maintenance is real, not just inertia

The most clarifying data here come from a trial that deliberately withdrew the drug. The STEP 1 trial extension, led by John Wilding and published in Diabetes, Obesity and Metabolism in 2022, followed 327 participants after both semaglutide and lifestyle support were stopped at week 68.

By week 68, the semaglutide group had lost about 17.3% of body weight (versus 2.0% on placebo). One year later, at week 120, they had regained roughly 11.6 percentage points — about two-thirds of their prior loss — leaving a net loss of around 5.6%.

Time point	Semaglutide	Placebo
Week 68 (on drug)	−17.3%	−2.0%
Week 120 (1 yr off drug)	−5.6% net	−0.1% net

The interpretation most researchers favor is straightforward: GLP-1s don’t permanently reset the body’s defended weight so much as continuously counteract the biology that drives regain. That reframes maintenance. It isn’t a victory lap; it is the medication doing ongoing work against appetite signaling and the metabolic adaptations that follow weight loss.

The honest read of the evidence: in the STEP 1 extension, stopping semaglutide was followed by regain of about two-thirds of lost weight within a year. For many people, weight maintenance on these drugs appears to depend on continued exposure. This is a long-term-condition framing, not a course-of-treatment one.

Practical implications worth knowing

• Dose during maintenance is an open question; some clinicians explore lower maintenance doses, but high-quality trials comparing maintenance dosing strategies are limited.
• Muscle preservation matters more in this phase — resistance training and adequate protein help ensure that what you hold is favorable body composition, not just a number.
• Stopping is a clinical decision, not a failure, and is best planned with a prescriber rather than done cold.

The takeaway

Active loss and maintenance are distinct goals, and the evidence suggests the drugs are doing genuine, continuous work in both phases. The STEP 1 withdrawal data make the central tension clear: these medications manage weight while present and tend not to leave a lasting metabolic imprint once removed — participants regained two-thirds of their loss within a year of stopping. Anyone choosing this path benefits from treating it as an indefinite-horizon decision and discussing the exit, if there is to be one, in advance.

Sources

• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (Diabetes, Obesity and Metabolism, 2022)